What is Customer Demographics and Target Market of Pacira Company?

Pacira Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What are Pacira BioSciences's customer demographics and target market?

Understanding customer demographics and target market is crucial for Pacira BioSciences, Inc.'s business strategy and market success, particularly given the significant demographic shift towards non-opioid pain management.

The ongoing opioid crisis has catalyzed a major cultural rethinking of pain treatment, creating a fertile environment for companies like Pacira, allowing it to emerge as a pioneer in non-opioid pain management.

Pacira's customer base and market position are firmly rooted in non-opioid pain management, primarily through its flagship product, EXPAREL. This strategic pivot aligns the company with a global healthcare trend, as the non-opioid pain treatment market was estimated at $48.38 billion in 2024 and is projected to reach approximately $96.25 billion by 2034, growing at a CAGR of 7.12% from 2025 to 2034. This sets the stage for exploring who Pacira's customers are, where they live, what they want, and how the company adapts to serve them in this evolving healthcare landscape. Learn more about the competitive forces in this sector through a Pacira Porter's Five Forces Analysis.

Pacira BioSciences primarily targets healthcare providers, including hospitals and ambulatory surgical centers, as its direct customers. The company's non-opioid pain management solutions ultimately benefit patients undergoing surgical procedures or managing chronic pain, representing an indirect consumer segment.

B2B Healthcare Providers

Pacira's core customer base consists of healthcare institutions such as hospitals and ambulatory surgical centers (ASCs). These entities are the purchasers and administrators of Pacira's pain management products.

Patient Demographics for Pain Management

The ultimate beneficiaries of Pacira's offerings are patients experiencing pain, particularly those undergoing surgery. This broad demographic spans various age groups and genders, reflecting the widespread need for effective pain relief.

EXPAREL Target Patients

EXPAREL is indicated for patients undergoing a wide array of surgical procedures. Key areas include women's health procedures like C-sections and mastectomies, as well as cardiothoracic surgery, where significant postsurgical pain is common.

ZILRETTA Target Patients

ZILRETTA targets patients suffering from osteoarthritis of the knee. This condition affects over 30 million adults in the U.S., with a notable prevalence in older populations, representing a substantial market segment.

The company's strategic focus, particularly its 5x30 strategy launched in January 2025, aims to accelerate growth in the U.S. commercial market. This includes prioritizing investments for separate Medicare reimbursement for EXPAREL in outpatient settings, effective January 2025. This new reimbursement pathway is anticipated to expand patient access in outpatient settings, potentially benefiting around 18 million outpatient surgical procedures annually, with an aim to reach over 3 million patients by 2030.

Pacira's Evolving Market Focus

Pacira BioSciences is strategically realigning its efforts to capitalize on new market opportunities. The company's market segmentation is increasingly influenced by regulatory changes and the expansion of product use in different healthcare settings.

• Expansion into outpatient settings for EXPAREL.
• Focus on Medicare reimbursement changes effective January 2025.
• Targeting approximately 18 million outpatient surgical procedures.
• Aiming to serve over 3 million patients annually by 2030.
• Understanding Target Market of Pacira is crucial for their growth strategy.

Pacira SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Pacira's customer base is primarily healthcare providers, with patients being the ultimate beneficiaries of their pain management solutions. The core need driving this market is effective, non-addictive pain relief, especially in light of the ongoing opioid crisis.

Post-Surgical Pain Management Needs

Healthcare providers and patients seek long-acting analgesia to minimize opioid use after surgery. This preference supports faster recovery and improved patient satisfaction.

Osteoarthritis Knee Pain Relief

Patients with osteoarthritis of the knee desire long-lasting, single-injection treatments. They prefer solutions that reduce the need for frequent office visits and provide reliable pain relief.

Demand for Non-Opioid Alternatives

There is a significant unmet need for drug-free pain control options. This trend influences product development and strategic initiatives within the pain management sector.

Preference for Reduced Opioid Exposure

Psychological and practical drivers favor solutions that reduce opioid exposure. This is due to concerns about addiction, side effects, and the desire for safer pain management.

Patient Satisfaction and Recovery

Faster recovery times and higher patient satisfaction are key preferences. Solutions that enable patients to return to normal activities sooner are highly valued.

Access to Outpatient Procedures

The implementation of the NOPAIN Act in January 2025, providing reimbursement for outpatient surgical procedures, aligns with the preference for expanded patient access and utilization in these settings.

Pacira BioSciences' target market is keenly focused on addressing the critical need for effective, non-addictive pain management solutions, a demand amplified by the ongoing opioid crisis. This focus shapes their customer profile, which includes healthcare providers seeking to reduce opioid exposure for their patients and patients themselves who prioritize safety and efficacy in pain relief.

Key Customer Needs and Preferences

Pacira's product development and strategic initiatives are directly influenced by market trends and customer feedback, particularly the strong push towards non-opioid alternatives in pain management.

• Postsurgical Pain: Preference for long-acting analgesia to minimize opioid use, leading to faster recovery and improved patient satisfaction. The NOPAIN Act's reimbursement pathway for outpatient procedures is a significant factor. In Q1 2025, there was a more than 30% increase in new and reactivated accounts for EXPAREL, indicating positive market reception.
• Osteoarthritis Knee Pain: Demand for long-lasting, single-shot treatments that offer reliable pain relief and reduce the frequency of office visits. ZILRETTA, a single-shot corticosteroid injection, addresses this need, providing up to four months of relief. A co-promotion agreement announced in July 2025 aims to expand ZILRETTA's availability and patient education.
• Drug-Free Pain Control: An unmet need exists for pain management solutions that do not involve pharmaceuticals. The iovera° system, utilizing cryoanalgesia, provides immediate and long-acting relief, catering to this preference.
• Innovation in Chronic Pain: Continued investment in advanced therapies, such as the gene therapy candidate PCRX-201 for knee osteoarthritis, demonstrates a commitment to addressing chronic pain and improving long-term patient outcomes. Promising two-year safety and efficacy data for PCRX-201 were reported in November 2024.

Understanding these customer needs and preferences is crucial for Pacira's continued success and aligns with their overall Growth Strategy of Pacira.

Pacira PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Pacira BioSciences has a strong geographical focus on the United States, which is its primary market for non-opioid pain management solutions. The company's operational presence is spread across key U.S. locations, including its headquarters in Brisbane, California, and offices in San Diego, California, Parsippany, New Jersey, and Tampa, Florida. This strategic positioning allows Pacira to effectively serve the significant North American market.

U.S. Market Dominance

The U.S. represents the largest segment of the non-opioid pain treatment market, valued at $17.08 billion in 2024. Pacira's efforts are heavily concentrated here, with initiatives like the NOPAIN Act's reimbursement pathway for its product in outpatient settings demonstrating a commitment to this region.

North American Market Significance

North America as a whole held a 37.5% share of the global non-opioid pain treatment market in 2024, estimated at $24.19 billion. This market is projected for robust growth, with an expected CAGR of 7.15% from 2025 to 2034.

Global Presence and Adaptation

While the U.S. is the primary focus, Pacira also maintains a presence in the UK, indicating a broader international outlook. Differences in customer demographics and market dynamics across regions are largely influenced by varying healthcare systems and reimbursement policies.

Strategic Focus and Restructuring

In February 2024, Pacira initiated a restructuring plan to reallocate resources towards its U.S. commercial portfolio, emphasizing investments for commercial readiness and strategic national accounts. The relocation of its corporate headquarters to Brisbane, California, in March 2025, further signals a strategic alignment with the biopharmaceutical hub and its 5x30 plan.

The company's strategic emphasis on the U.S. market is further evidenced by its restructuring plan initiated in February 2024. This plan involved reallocating efforts and resources to its commercial portfolio within the U.S., prioritizing investments for commercial readiness related to the NOPAIN Act, and concentrating on broader commercial initiatives in strategic national accounts, marketing, and market access. This demonstrates a clear intent to deepen its penetration and market share within the United States. The recent relocation of its corporate headquarters to Brisbane, California, in March 2025, aligns with its 5x30 plan, aiming to transition into an innovative biopharmaceutical organization within the South San Francisco biopharmaceutical hub. This move underscores a strategic commitment to leveraging key geographical and industry ecosystems. Understanding these geographical nuances is crucial for grasping the Marketing Strategy of Pacira and its target market.

U.S. Market Value

The North American non-opioid pain treatment market was valued at $24.19 billion in 2024, with the U.S. accounting for $17.08 billion of this total.

Projected Growth

The North American market is projected to grow at a CAGR of 7.15% from 2025 to 2034, while the U.S. market is expected to grow at a CAGR of 8% during the same period.

Market Share

In 2024, North America held a significant 37.5% share of the global non-opioid pain treatment market.

Regulatory Impact

Government initiatives in the U.S. to reduce opioid usage and advancements in healthcare infrastructure are key drivers for non-opioid solutions, with the NOPAIN Act being a prime example.

Strategic Realignment

A restructuring plan in February 2024 focused on reallocating resources to the U.S. commercial portfolio and prioritizing investments for commercial readiness.

Headquarters Relocation

The corporate headquarters moved to Brisbane, California, in March 2025, aligning with the company's strategic plan to transition into an innovative biopharmaceutical organization.

Pacira Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Pacira BioSciences focuses on acquiring and retaining healthcare professionals and institutions by highlighting the clinical benefits and opioid-sparing advantages of its pain management solutions. The company actively promotes real-world data and educational campaigns to reach its target audience.

Customer Acquisition Drivers

The company emphasizes the clinical efficacy and opioid-sparing benefits of its products, particularly EXPAREL, to attract new users. Real-world studies demonstrating economic advantages and national awareness campaigns are key acquisition tools.

Targeted Marketing and Sales

Marketing efforts are directed towards surgeons, anesthesiologists, and hospital administrators. Direct engagement with healthcare facilities aims to secure formulary approvals for products like EXPAREL.

Impact of NOPAIN Act

The implementation of the NOPAIN Act in January 2025 is a significant acquisition strategy, creating a separate Medicare reimbursement pathway for EXPAREL in outpatient settings. This is expected to boost utilization for millions of outpatient surgical procedures.

Retention Through Value Proposition

Customer retention is built on the ongoing value of non-opioid pain management and addressing unmet medical needs. A co-promotion agreement for ZILRETTA aims to expand its market reach and support professional education.

Pacira leverages customer data and market insights to refine its strategies and product development, aiming to reach over 3 million patients annually by 2030 through its '5x30' strategy. This long-term vision, coupled with pipeline advancements and strategic resource allocation, like the focus on the U.S. commercial market in February 2024, underscores a commitment to sustained growth and customer loyalty. Understanding the Revenue Streams & Business Model of Pacira provides further context for these customer-centric initiatives.

Clinical Efficacy Promotion

Highlighting the proven effectiveness and opioid-sparing properties of products like EXPAREL is central to attracting new healthcare providers and institutions.

Economic Benefit Data

Presenting real-world studies that demonstrate the economic advantages of their non-opioid pain management solutions helps to persuade decision-makers in healthcare facilities.

Reimbursement Pathway Optimization

The NOPAIN Act's introduction of a separate Medicare reimbursement pathway for EXPAREL in outpatient settings is a critical factor for driving adoption and expanding patient access.

Strategic Partnerships

Collaborations, such as the co-promotion agreement for ZILRETTA, are utilized to broaden product availability and enhance professional education, thereby strengthening market presence.

Long-Term Growth Strategy

The '5x30' strategy, aiming for significant patient reach and revenue growth by 2030, guides sustained efforts in customer acquisition and retention through innovation.

Pipeline Development

Investing in the development of new therapies, like PCRX-201 for osteoarthritis, demonstrates a commitment to addressing evolving patient needs and maintaining market relevance.

Pacira Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔